RQ 00201894
Alternative Names: RQ-00201894Latest Information Update: 17 Apr 2024
At a glance
- Originator Pfizer
- Developer RaQualia Pharma
- Class Gastrokinetics; Indoles; Small molecules
- Mechanism of Action Motilin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gastroparesis; Postoperative ileus
- No development reported Non-ulcer dyspepsia
Most Recent Events
- 17 Apr 2024 Preclinical development is ongoing for Gastroparesis and Postoperative-ileus in Japan (PO) (RaQualia Pharma pipeline, April 2024)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Gastroparesis in Japan (PO)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Non-ulcer-dyspepsia in Japan (PO)